Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

20101,669 citationsJournal Articlebronze Open Access

Authors

Giuseppe Saglio · Ospedale San Luigi Gonzaga

Dong‐Wook Kim · Catholic University of Korea

Surapol Issaragrisil · Mahidol University

P. Le Coutre · Charité - Universitätsmedizin Berlin

Gabriel Étienne · Institut Bergonié

Clarisse Lobo · Hemorio

Ricardo Pasqüini ·

Abstract

Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.)

Topics & Keywords

Chronic Myeloid Leukemia Treatments Eosinophilic Disorders and Syndromes Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 24, pp. 2251-2259

DOI: 10.1056/nejmoa0912614

Field-Weighted Citation Impact: 95.14